TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy

Molecular Neurodegeneration

Volumn 12, Issue 1, 2017, Pages

  Bemiller, Shane M ^a,b,c   McCray, Tyler J ^c   Allan, Kevin ^d   Formica, Shane V ^a   Xu, Guixiang ^a,c   Wilson, Gina ^e   Kokiko Cochran, Olga N ^a,f   Crish, Samuel D ^e   Lasagna Reeves, Cristian A ^c   Ransohoff, Richard M ^g   Landreth, Gary E ^c,d   Lamb, Bruce T ^a,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g BIOGEN   (United States)

Author keywords

Alzheimers disease; Immunity; Inflammation; Tauopathy; TREM2

Indexed keywords

PHOSPHOTRANSFERASE; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; PROTEIN KINASE; TREM2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS; TAUOPATHY; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; HUMAN; METABOLISM; MICROGLIA; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; PROTEIN KINASES; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; TAU PROTEINS; TAUOPATHIES;

EID: 85031702585     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/s13024-017-0216-6     Document Type: Article

References (36)

1. Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429-35. doi: 10.1038/ng.803.
2. Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094-9. doi: 10.1038/ng.439.
3. Naj A, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43:436-41. doi: 10.1038/ng.801.
4. Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2012; doi: 10.1056/NEJMoa1211851.
5. Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2012; doi: 10.1056/NEJMoa1211103.
6. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol. 2003;3:445-53. doi: 10.1038/nri1106.
7. Hsieh C, et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem. 2009;109:1144-56. doi: 10.1111/j.1471-4159.2009.06042.x.
8. Sieber M, et al. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982. doi: 10.1371/journal.pone.0052982.
9. Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis. 2005;18:314-22. doi: 10.1016/j.nbd.2004.09.007.
10. Linnartz B, Wang Y, Neumann H. Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int J Alzheimers Dis. 2010; doi: 10.4061/2010/587463 (2010). (2010).
11. Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and Neurodegeneration. ACS Chem Neurosci. 2016; doi: 10.1021/acschemneuro.5b00313.
12. Savage JC, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. J Neurosci. 2015;35:6532-43. doi: 10.1523/JNEUROSCI.4586-14.2015.
13. Bird TD, Koerker RM, Leaird BJ, Vlcek BW, Thorning DR. Lipomembranous polycystic osteodysplasia (brain, bone, and fat disease): a genetic cause of presenile dementia. Neurology. 1983;33:81-6.
14. Chouery E, et al. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum Mutat. 2008;29:E194-204. doi: 10.1002/humu.20836.
15. Klunemann H, et al. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502-7. disease. J Neurosci. 2005;64:1502-7. doi: 10.1212/01.WNL.0000160304.00003.CA.
16. Numasawa Y, et al. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur J Neurol. 2011;18:1179-83. doi: 10.1111/j.1468-1331.2010.03311.x.
17. Cady J, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71:449-53. doi: 10.1001/jamaneurol.2013.6237.
18. Borroni B, et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35 doi: 10.1016/j.neurobiolaging.2013.09.017. ARTN 934.e7.ARTN 934.e7.
19. Rayaprolu S, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener. 2013;8 doi: 10.1186/1750-1326-8-19. Artn 19.Artn 19.
20. Jay TR, et al. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015;212:287-95. doi: 10.1084/jem.20142322.
21. Ulrich JD, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20. doi: 10.1186/1750-1326-9-20.
22. Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci. 2017;37:637-647. doi: 10.1523/JNEUROSCI.2110-16.2016.
23. Wang Y, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213:667-75. doi: 10.1084/jem.20151948.
24. Wang YM, et al. TREM2 lipid sensing sustains the Microglial response in an Alzheimer's disease model. Cell. 2015;160:1061-71. doi: 10.1016/j.cell.2015.01.049.
25. Andorfer C, et al. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446-54.
26. Andorfer C, et al. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem. 2003;86:582-90.
27. Julien C, Bretteville A, Planel E. Biochemical isolation of insoluble tau in transgenic mouse models of tauopathies. Methods Mol Biol. 2012;849:473-91. doi: 10.1007/978-1-61779-551-0-32.
28. Jay TR, et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J Neurosci. 2016; doi: 10.1523/jneurosci.2110-16.2016.
29. Bhaskar K, et al. Regulation of tau pathology by the microglial fractalkine receptor. Neuron. 2010;68:19-31. doi: 10.1016/j.neuron.2010.08.023.
30. Maphis N, et al. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain. 2015;138:1738-55. doi: 10.1093/brain/awv081.
31. Kokiko-Cochran O, et al. Altered Neuroinflammation and Behavior after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease. J Neurotrauma. 2015; doi: 10.1089/neu.2015.3970.
32. Asai H, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18:1584-93. doi: 10.1038/nn.4132.
33. Pooler AM, Phillips EC, Lau DHW, Noble W, Hanger DP. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 2013;14:389-94. doi: 10.1038/embor.2013.15.
34. Lee S, et al. Opposing effects of membrane-anchored CX3CL1 on Amyloid and tau pathologies via the p38 MAPK pathway. J Neurosci. 2014;34:12538-46. doi: 10.1523/jneurosci.0853-14.2014.
35. Ghosh S, et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci. 2013;33:5053-64. doi: 10.1523/JNEUROSCI.4361-12.2013.
36. Zhong L, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017; doi: 10.1084/jem.20160844.